NCIt definition : A human immunoglobulin G2 (IgG2) monoclonal antibody against activin receptor-like
kinase-1 (ALK-1; ALK1), with potential anti-angiogenic and antineoplastic activities.
Upon administration, ascrinvacumab targets and binds to ALK-1, and prevents ALK-1
activation by its ligands bone morphogenetic protein 9 (BMP) 9 and BMP10. This prevents
ALK-1-mediated endothelial cell signaling and the activation of transforming growth
factor-beta (TGF-beta)/TGF-beta receptor I (ALK-5) signaling. This inhibits tumor
blood vessel growth, reduces blood flow and angiogenesis and leads to an inhibition
of tumor cell proliferation and modulation of the tumor microenvironment (TME). ALK-1,
a member of the transforming growth factor beta (TGF-b) type I receptor family, is
overexpressed on endothelial cells in a variety of tumor cell types and increases
endothelial cell proliferation and migration.;
UNII : 716FQ5REVO;
CAS number : 1463459-96-2;
Molecule name : PF-03446962; GT-90001; GT 90001; PF 03446962;